מדינה: ניו זילנד
שפה: אנגלית
מקור: Medsafe (Medicines Safety Authority)
Furosemide 10mg
Baxter Healthcare Ltd
Furosemide 10 mg
10 mg/mL
Solution for injection
Active: Furosemide 10mg Excipient: Hydrochloric acid Sodium hydroxide pH adjustment Sodium chloride Sodium hydroxide Water for injection
Ampoule, glass, Type I amber glass ampoule, 5 mL, 5 dose units
Prescription
Prescription
Ipca Laboratories Limited
Furosemide-Baxter Injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.
Package - Contents - Shelf Life: Ampoule, glass, Type I amber glass ampoule, 5 mL - 5 dose units - 3 years from date of manufacture stored at or below 25°C - Ampoule, glass, Type I amber glass ampoule,2 mL - 5 dose units - 3 years from date of manufacture stored at or below 25°C - Ampoule, glass, Type I amber glass ampoule, 5mL - 25 dose units - 3 years from date of manufacture stored at or below 25°C - Ampoule, glass, Type I amber glass ampoule, 2 mL - 25 dose units - 3 years from date of manufacture stored at or below 25°C
2009-05-04
NEW ZEALAND DATA SHEET Furosemide‐Baxter Data Sheet 15 October 2019 Page 1 of 14 Baxter Healthcare Ltd 1 FUROSEMIDE‐BAXTER (10mg/mL solution for injection) FUROSEMIDE‐BAXTER 10mg/mL solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION FUROSEMIDE‐BAXTER solution for injection contains 10mg frusemide per mL. FUROSEMIDE‐BAXTER is available in 2mL and 5mL ampoules which contain 20mg/2mL and 50mg/5mL respectively. _Excipients with known effect _ Sodium chloride and sodium hydroxide. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. _Appearance _ FUROSEMIDE‐BAXTER solution for injection is a clear colourless solution for injection. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications _OEDEMA _ FUROSEMIDE‐BAXTER solution for injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. Frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. FUROSEMIDE‐BAXTER solution for injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. Parenteral use should be replaced with oral frusemide as soon as practical. 4.2 Dose and method of administration _Adults _ Parenteral therapy with FUROSEMIDE‐BAXTER solution for injection should be used only in patients unable to take oral medication or in emergency situations and should be replaced with oral therapy as soon as practical. _Oedema_ The usual initial dose of FUROSEMIDE‐BAXTER is 20 to 40mg given as a single dose, injected intramuscularly קרא את המסמך השלם